Meet our Leaders
Our Leadership Team includes physicians, professionals, students, patient volunteers, and physician-entrepreneurs with a tremendous amount of disease-specific knowledge, organizational management skills, and start-up experience.
David Fajgenbaum
, MD, MBA, MSc, FCPP
Co-Founder & President
Dr. David Fajgenbaum, MD, MBA, MSc, FCPP, is the co-founder and President of the Castleman Disease Collaborative Network (CDCN), Founding Director of the Center for Cytokine Storm Treatment & Laboratory (CSTL), Associate Director of Patient Impact for the Penn Orphan Disease Center, and Associate Professor of Medicine in Translational Medicine & Human Genetics at the University of Pennsylvania. Dr. Fajgenbaum is also the national bestselling author of Chasing My Cure: A Doctor’s Race to Turn Hope Into Action and a patient battling idiopathic multicentric Castleman disease (iMCD). He became ill during his third year of medical school in 2010, had his last rites read, and had four deadly iMCD relapses. In 2012, Dr. Fajgenbaum co-founded the CDCN, through which he has spearheaded the “Collaborative Network Approach.” (more)
Frits van Rhee,
MD, PhD
Co-Founder & Co-Chair of Scientific Advisory Board
Frits van Rhee, MD, PhD, co-founded the Castleman Disease Collaborative Network. He is a Professor of Medicine and Director of Developmental and Translational Medicine at the UAMS Myeloma Institute. He earned his medical degree from Erasmus University, Rotterdam, Netherlands and his PhD at the Imperial College of Science, Medicine and Technology, University of London. Dr. van Rhee trained in Internal Medicine and Hematology in the UK, and in Bone Marrow Transplantation at John Radcliffe University Hospital in Oxford and the Royal Postgraduate Medical School in London. He holds the Charles and Clydene Scharlau Chair for Hematological Malignancies. (more)
Madison Ahearn, MHA
Director of Programming and Operations
Madison Ahearn is the Director of Programming and Operations at the CDCN. Madison serves the Castleman disease community of patients, loved ones, physicians, and researchers. Prior to this role, Madison was with Penn Medicine Academy, where she developed strategic planning, change management and leadership skills. Madison also worked as a Research Assistant at Temple University’s Pathology and Laboratory Medicine lab, where she studied the impact of traumatic brain injuries on the blood brain barrier and how multiple repeated TBIs increased the likelihood of developing substance abuse disorders. She is passionate about medical science and engaging with the patient community to help guide them through their battle with Castleman disease.
Madison has a BS in Neuroscience and a Master of Health Administration from Temple University. She also received a Certificate in Healthcare Innovation Management.
Martin Lukac, MD, PhD, MPH
European Communications and ACCELERATE Registry Lead
Martin Lukac is board certified in Clinical Pharmacology with more than 20 years of experience in clinical development. Martin is passionate about clinical research, which was the reason to study this specialization at the University of London where he received a Postgraduate Diploma in Clinical Trials. He is currently based in Prague where he works as a Medical Director at PAREXEL. In cooperation with Dr. Fajgenbaum on the ACCELERATE global patient registry, Martin decided to join the CDCN as a volunteer to help spread awareness about Castleman Disease in Europe.
Sheila Pierson, MS
Senior Research Advisor
Sheila Pierson, MS is a Senior Research Advisor for the Castleman Disease Collaborative Network (CDCN). Since 2016, she has been a pivotal figure in the Castleman disease field and has published extensively on disease subgroups and treatment patterns that inform clinical practice. Previously, Sheila served as the Director of Clinical Research for the Center for Cytokine Storm Treatment & Laboratory (CSTL) at the University of Pennsylvania, where she made significant contributions to Castleman research through her oversight of the ACCELERATE Registry and her biostatistical analyses of large-scale proteomics datasets. She holds an MS in nutrition from Columbia University and an MS in biostatistics from the University ofPennsylvania, and she is currently pursuing her medical degree at the Lewis Katz School of Medicine at Temple University. Sheila’s multifaceted expertise and commitment to advancing Castleman disease research are shaping the future of treatment options for this vulnerable community.
Colin Smith, PhD
Senior Collaborative Research Advisor
Colin received his BA from Macalester College and his PhD from the University of Pennsylvania, both in Neuroscience. During the day, Colin is a Strategic Science and Academic Innovation Manager at EMD Serono, a global specialty pharmaceutical company with a focus on oncology, immuno-oncology, and immunology. He previously served as a Licensing Manager at Partners Healthcare Innovation. Prior to joining Partners, he was a Senior Associate in the Business Development office at The Wistar Institute where he was introduced to the work of the CDCN. He’s passionate about basic research and translating exciting research findings into the clinic.
Caitlin Fajgenbaum
Co-Chair Quest for a Cure
Caitlin Fajgenbaum is a Strategic Communications Advisor for the CDCN. Caitlin is passionate about fighting back against Castleman disease and wants to help others to fight back too. Caitlin’s nonprofit work dates back to when she organized the inaugural National Conference on College Student Grief and started a chapter of Students of AMF, a grief support network, while she was a sophomore at Meredith College. Under her leadership, the organization participated in community service projects throughout the Raleigh-area and developed a deep, meaningful support group. Caitlin graduated from Meredith College, where she received a BS in Fashion Merchandising & Design.
Mileva Repasky, MS
Co-Chair Quest for a Cure
Mileva Repasky is the mother to one of our youngest Castleman Disease patients, Katie. She is passionate about connecting patients and loved ones, fundraising, patient advocacy, and raising awareness. She will continue to advance the CDCN’s mission by collaborating with the patient and loved one community, physicians, researchers, and our partners, to advance our life saving mission. She is particularly interested in finding new and innovative ways to raise awareness of this disease.
Mileva graduated with a BS in Psychology and completed her Masters in Clinical Psychology in 2016. Mileva began as a volunteer with the CDCN in 2014.